Compare MIRM & BLCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MIRM | BLCO |
|---|---|---|
| Founded | 2018 | 1853 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Ophthalmic Goods |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.7B | 5.9B |
| IPO Year | 2019 | 2022 |
| Metric | MIRM | BLCO |
|---|---|---|
| Price | $101.26 | $15.64 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 13 | 11 |
| Target Price | ★ $119.85 | $18.45 |
| AVG Volume (30 Days) | ★ 1.0M | 414.0K |
| Earning Date | 05-06-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 74.59 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $19,138,000.00 | ★ $5,101,000,000.00 |
| Revenue This Year | $26.22 | $8.65 |
| Revenue Next Year | $22.04 | $5.59 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 6.47 |
| 52 Week Low | $43.50 | $11.22 |
| 52 Week High | $114.99 | $18.92 |
| Indicator | MIRM | BLCO |
|---|---|---|
| Relative Strength Index (RSI) | 51.95 | 39.74 |
| Support Level | $95.68 | $15.20 |
| Resistance Level | $107.51 | $16.41 |
| Average True Range (ATR) | 5.22 | 0.36 |
| MACD | -0.65 | -0.04 |
| Stochastic Oscillator | 33.42 | 23.76 |
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.